# ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-to-participate-in-upcoming-investor-conferences-195e8a5d
Ticker: SPRY
Company: ARS Pharmaceuticals
Source: ARS Pharmaceuticals
Published: 2026-09-01 20:01 EST
## Summary

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk...

## Article Body
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergic reactions, today announced that Donn Casale, President and CEO, will participate in the following September investor conferences.

Wells Fargo Healthcare Conference

1x1 Investor Meetings: Wednesday, September 9, 2026

Location: Boston

Cantor Global Healthcare Conference

Fireside Chat: Friday, September 11, 2026, 8:35 a.m. ET

1x1 Investor Meetings: Thursday, September 10, 2026

Location: New York

To access the live and archived webcast from the Cantor Global Healthcare Conference, please visit the Events & Presentations page in the “Investors & Media” section of the Company’s website. A replay will remain available for 30 days following the event.

About ARS Pharmaceuticals, Inc.

ARS Pharma is a biopharmaceutical company developing and commercializing treatments that help at-risk patients and their caregivers treat and prevent severe allergic reactions. The company is commercializing neffy ® (epinephrine nasal spray), the only needle-free epinephrine approved by the U.S. Food & Drug Administration and European Medicines Agency, for the emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children weighing 33 lbs. (15kg) or more. The product is marketed as EUR neffy ® in the European Union and as 优敏速 ® in China. Leveraging its intranasal technology, ARS Pharma is also developing ARS-2, currently in a Phase 2b clinical trial, as a potential first treatment for acute flares of chronic spontaneous urticaria (CSU). For more information, visit www.ars-pharma.com and follow us on LinkedIn and X .

ARS Investor Contact: Monique Allaire, THRUST monique@thrustsc.com

ARS Media Contact: Christy Curran, Sam Brown Inc. 615.414.8668 christycurran@sambrown.com
## Recent Company News
- 2026-09-01 20:01 EST — [ARS Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-to-participate-in-upcoming-investor-conferences-195e8a5d) — Source: ARS Pharmaceuticals
- 2026-08-13 20:01 EST — [ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-outlines-strategic-priorities-including-a-focused-commercial-788a83c6) — Source: ARS Pharmaceuticals
- 2026-08-03 11:30 EST — [ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-announces-conference-call-and-webcast-on-august-13-outlining-0390283c) — Source: ARS Pharmaceuticals
- 2026-07-07 20:30 EST — [ARS Pharmaceuticals Announces CEO Succession](https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-announces-ceo-succession-533f8792) — Source: ARS Pharmaceuticals
- 2026-06-24 20:05 EST — [ARS Pharmaceuticals Provides Commercial and Financial Updates](https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-provides-commercial-and-financial-updates-8c04d85d) — Source: ARS Pharmaceuticals
## Related News
- 2026-09-06 05:00 EST — ROIV — [Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call](https://biopharmsignal.com/news/ROIV/roivant-to-present-topline-results-from-the-phase-2-phocus-study-of-mosliciguat--bf1ea553)
- 2026-09-04 20:30 EST — ORIC — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e23953dd)
- 2026-09-04 20:05 EST — RPID — [Rapid Micro Biosystems to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-upcoming-investor-conferences-91a8800f)
- 2026-09-04 20:05 EST — LIXT — [NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS](https://biopharmsignal.com/news/LIXT/nomad-power-solutions-announces-adjournment-of-special-meeting-of-stockholders-74cd9e2e)
- 2026-09-04 20:05 EST — AVTX — [Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-lis-cc7baaf2)